
Applied Nutrition has posted higher revenue and profit as the sports supplement maker cashes in on the growing popularity of weight-loss jabs.
The London-listed group nearly doubled its profit in the year to the end of July, boosted by its efforts to create supplements for consumers using weight loss jabs, or GLP-1s.
The surge in popularity of these treatments is partly to blame for the soaring cost of whey protein, a crucial ingredient for the products made by Applied Nutrition, which has eaten into the firm’s margins in recent months.
But the London-listed group has sought to capitalise on the demand for fitness supplements among Brits using weight-loss jabs, creating the first range of protein shakes which specifically targets these consumers.
These products include creatine and liquid collagen pouches and “digest capsules” featuring enzymes, probiotics and fibre to “promote digestive comfort” and “gut health”.
Stay in the know
Three daily briefings with the key market moves and top business and political stories.
SUBSCRIBE HERE“The global sports nutrition, health and wellness market continues to grow rapidly as consumers are becoming more health conscious,” the group told shareholders.
The number of British consumers using weight-loss medication has surged from 3.1 per cent in June last year to six per cent in March this year, it said, citing research from the Institute of Grocery Distribution.
“These shifting trends are creating opportunities across both established and emerging categories,” the firm said. Its new GLP-1-friendly ranges have “helped us remain at the forefront of the market while retaining the agility to adapt as demand changes,” it added.
Alongside the rising popularity of weight-loss drugs, female gym-goers are driving higher demand for products like collagen and creatine, Applied Nutrition said.
Rooney and Issa among backers
The Merseyside-based group said its GLP-1 ranges had helped it to grow its revenue by a half to £161.6m in the year to the end of July, lifting its pre-tax profit by 44 per cent to £40.6m.
As well as targeting GLP-1 users, it has embraced partnerships with brands like Slush Puppie, Sour Patch Kids and Swedish Fish in a bid to stay relevant with younger consumers.
Thomas Ryder, the former scaffolder who founded the business in 2014, said the group is entering its new financial year with “very strong momentum”.
“Consumer demand for health, wellness and performance nutrition continues to grow and the market is moving quickly. We stay close to our customers, listen to what consumers want and move fast when we see an opportunity.”
Since it was founded little more than a decade ago, Applied Nutrition’s rapid rise has been buoyed by high-profile backers including Colleen Rooney, former JD Sports boss Peter Cowgil and petrol forecourt magnate Mohsin Issa.
Milo Bussell, an analyst at stock broker Cavendish, said the protein shake maker is “going from strength to strength”. The firm’s market backdrop is “highly supportive with consumers prioritising health and wellness and retailers expanding shelf space for the category,” he said.
Applied Nutrition has been one of London’s biggest success stories since its IPO in October 2024, with its shares up 133 per cent since its first day of trading. London’s stock exchange has suffered from a dearth of big-ticket listings in the two years since.
Ryder told : “We’re honoured and privileged to be part of the LSE. We set out to be successful on the London Stock Exchange, and we have been, thankfully, and we just keep wanting to under-promise and over-deliver.
“As for the lack of other IPOs, I’m not too sure, if I’m totally honest, but what I can say is it’s been a great decision for us, for Applied Nutrition, and we encourage anybody else to take the same risk.”